$3.60
0.28% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US81749D1072
Symbol
SERA

Sera Prognostics Inc - Ordinary Shares Class A Stock price

$3.60
+0.22 6.51% 1M
+1.57 77.34% 6M
-4.54 55.77% YTD
-4.35 54.72% 1Y
+2.00 125.00% 3Y
-8.30 69.75% 5Y
-8.30 69.75% 10Y
-8.30 69.75% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.01 0.28%
ISIN
US81749D1072
Symbol
SERA
Industry

Key metrics

Basic
Market capitalization
$138.9m
Enterprise Value
$95.6m
Net debt
positive
Cash
$43.3m
Shares outstanding
38.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,389.4 | 1,433.8
EV/Sales
956.4 | 987.0
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
65.9%
Return on Equity
-68.8%
ROCE
-43.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$100.0k | $96.9k
EBITDA
$-36.1m | $-34.2m
EBIT
$-37.0m | $-38.9m
Net Income
$-32.6m | $-27.5m
Free Cash Flow
$-26.2m
Growth (TTM | estimate)
Revenue
11.1% | 21.1%
EBITDA
-2.4% | 4.6%
EBIT
-2.5% | -6.3%
Net Income
-1.2% | 16.3%
Free Cash Flow
-66.4%
Margin (TTM | estimate)
Gross
-62.1%
EBITDA
-37,964.2% | -35,263.2%
EBIT
-38,919.0%
Net
-34,343.2% | -28,420.0%
Free Cash Flow
-27,600.0%
More
EPS
$-0.7
FCF per Share
$-0.7
Short interest
1.3%
Employees
64
Rev per Employee
$0.0
Show more

Is Sera Prognostics Inc - Ordinary Shares Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Sera Prognostics Inc - Ordinary Shares Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Sera Prognostics Inc - Ordinary Shares Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Sera Prognostics Inc - Ordinary Shares Class A forecast:

Buy
88%
Hold
13%

Financial data from Sera Prognostics Inc - Ordinary Shares Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.10 0.10
11% 11%
100%
- Direct Costs 0.15 0.15
88% 88%
150%
-0.06 -0.06
400% 400%
-60%
- Selling and Administrative Expenses 24 24
16% 16%
23,820%
- Research and Development Expense 13 13
15% 15%
13,090%
-36 -36
2% 2%
-36,070%
- Depreciation and Amortization 0.91 0.91
10% 10%
910%
EBIT (Operating Income) EBIT -37 -37
3% 3%
-36,973%
Net Profit -33 -33
1% 1%
-32,630%

In millions USD.

Don't miss a Thing! We will send you all news about Sera Prognostics Inc - Ordinary Shares Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sera Prognostics Inc - Ordinary Shares Class A Stock News

Neutral
PRNewsWire
about one month ago
The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY , Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors an...
Neutral
Seeking Alpha
about one month ago
Sera Prognostics, Inc. ( SERA ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Jennifer Zibuda - Head of Investor Relations Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division Margarate Boeye - William Blair & Company L.L.C., Research Division Presentation Operat...
Neutral
PRNewsWire
about one month ago
SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer i...
More Sera Prognostics Inc - Ordinary Shares Class A News

Company Profile

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Evguenia Lindgardt
Employees 64
Founded 2008
Website www.sera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today